Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.
- Registry ID
- EUCTR2014-001620-29
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE2
- Sponsor
- Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)
- Start date
- 2014-10-19
- Last update
- 2026-08-16
Conditions
- Refractory Diffuse large B-cell lymphoma.
Summary
To determine the response rate with the combination of lenalidomide and chemotherapy type R-GDP (Rituximab, Gemcitabine, Dexamethasone and Cisplatin) in patients with relapsed or refractory diffuse large B-cell lymphoma not candidates for high-dose chemotherapy nor transplantation of cells hematopoietic progenitors.
Locations
View on source registry